title: [Hormone therapy of postoperative recurrent pancreatic carcinoma with octreotide and tamoxifen].
abstract: BACKGROUND
  In a prospective trial (October 1996-April 1998) the effect of octreotide and tamoxifen on the recurrence of pancreatic carcinoma after R0 resection was evaluated.
  
  
  METHODS
  Patients with a local recurrence after curative resection of ductal adenocarcinoma of the pancreas were treated with 100 micrograms of octreotide three times a day and tamoxifen 20 mg once daily. The median survival time, quality of life (EO-RTC-QLQ-30) and side effects of the octreotide-tamoxifen group were compared with a historic cohort (n = 14) of patients treated in our department (9/95-9/96) according to the "best supportive care" concept.
  
  
  RESULTS
  Recurrences were diagnosed after R0 resection in a mean time of 13 +/- 6.8 months. Patients treated with octreotide and tamoxifen had a significantly (P < 0.05) longer median survival time (7 months; range: 3-12) vs 3.5 months; range: 1.5-5). The octreotide-tamoxifen group suffered less from lack of appetite, nausea, fatigue, and pain and needed fewer analgesics. The only side effect of the octreotide-tamoxifen therapy was moderate diarrhea in 2 patients at the beginning of the therapy.
  
  
  CONCLUSIONS
  Since combined therapy with octreotide and tamoxifen can be administered comfortably for outpatient treatment, this seems to represent progress in the palliative therapy of pancreatic cancer.
authors.affiliation: Klinik für Allgemein-, Viszeral-, Gefäss- und Thoraxchirurgie, Universitätsklinikum Charité Campus Mitte, Humboldt-Universität Berlin.
authors.forename: F A
authors.initials: FA
authors.lastname: Wenger
authors.forename: C A
authors.initials: CA
authors.lastname: Jacobi
authors.forename: A
authors.initials: A
authors.lastname: Siderow
authors.forename: J
authors.initials: J
authors.lastname: Zieren
authors.forename: H U
authors.initials: HU
authors.lastname: Zieren
authors.forename: J M
authors.initials: JM
authors.lastname: Müller
mesh_terms: D000368:Aged; D018931:Antineoplastic Agents, Hormonal / Q000008:administration & dosage* / Q000009:adverse effects; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D017024:Chemotherapy, Adjuvant; D003131:Combined Modality Therapy; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy* / Q000601:surgery; D015282:Octreotide / Q000008:administration & dosage* / Q000009:adverse effects; D010180:Pancreatectomy; D010190:Pancreatic Neoplasms / Q000188:drug therapy* / Q000601:surgery; D011788:Quality of Life; D015996:Survival Rate; D013629:Tamoxifen / Q000008:administration & dosage* / Q000009:adverse effects
chemical_list: D018931:Antineoplastic Agents, Hormonal; D013629:Tamoxifen; D015282:Octreotide
vernacular_title: Hormontherapie des postoperativ rezidivierten Pankreascarcinoms mit Octreotid und Tamoxifen.